We are proud to announce that our THC:CBD combinations have reached 6-month ICH stability. Coupled with Swissmedic’s recent approval to include THC and combination products in our GMP certification, these formulations are now eligible for pharmaceutical development, through the finalization of our Drug Master File.
This stability milestone means that our products maintain their premium quality over time, ensuring consistent reliability for healthcare professionals and for patients. It reflects our commitment to rigorous quality standards and continuous innovation in the cannabinoid space.
Accomplishments like this further reinforce and demonstrate our dedication to highly distinguished, scientifically validated cannabinoids.
